Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
how glad I am to have loaded at $120!
I will keep them for a long time!
The approval is based on positive data from the Company’s two Phase 3 PRIMROSE trials. The pooled week 24 data from these studies support a potentially best-in-class profile, with a responder rate of 84.5% in women receiving linzagolix 200 mg with hormonal ABT, and 56.5% in women receiving linzagolix 100 mg without ABT.
The NDA for linzagolix in the U.S. is currently under review by the FDA, with a PDUFA target action date of September 13, 2022
ObsEva today announced that the European Commission (EC) has granted marketing authorization for Yselty® (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.
Miiiinchia! (typical Sicilian expression) How do you read far!
I don't think he's done!
MDT
Cambridge Design
Benchmark Electronics
they are respectable names and they are involved here!
I see a third way!
we need the toy to be ready and when it's up and running someone interested is there!
MDT could pay for the right to sell it in the non-US market, all to finance the shack.
Or they could just buy something like 5%
Ready and working
It could be but I like to dream!
Going short is like using gravity! Sooner or later it will lay you down!
Convenient repetitive for those who do it for a living! Frankly I think it is as hateful as mosquitoes!
I profit on your few mistakes!
I hope you are wrong!
At least for a while!
no more Research & Development
Perry Genova gone
Time for Manufacturing and Operations
Bill Fahey arrived
For me it is cooked
Completion of Product Development!
Come on Paul Cat make us excited!
In my opinion this makes someone happy! (MDT)
a gesture of gratitude is welcome
it is in everyone's interest!
who knows what will happen?
https://pdfpiw.uspto.gov/.piw?PageNum=3&docid=11357528&IDKey=32A4C28D47D6%0D%0A&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
https://pdfpiw.uspto.gov/.piw?PageNum=4&docid=11357528&IDKey=32A4C28D47D6%0D%0A&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
https://pdfpiw.uspto.gov/.piw?PageNum=5&docid=11357528&IDKey=32A4C28D47D6%0D%0A&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
Milestones still hang
In June 2005, we entered into an acquisition agreement with Cephalon, Inc., or Cephalon, pursuant to which we divested the compound,
TRISENOX. Cephalon was subsequently acquired by Teva Pharmaceutical Industries Ltd., or Teva. Under this agreement, we have the right to receive up
to $100 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX. To date, we have received
$60.0 million of such potential milestone payments as a result of having achieved certain sales milestones.
time is short but the need is high! Is it possible that no commercialization will be viable in the short term?
https://www.ema.europa.eu/en/documents/withdrawal-letter/withdrawal-letter-enpaxiq_en.pdf
Graig, then what are you doing for Europe?
As the commercial launch of VONJOTM (pacritinib) in the U.S. continues to exceed our expectations, we are pleased to highlight VONJO's clinical value as a potential best in class treatment for patients with cytopenic myelofibrosis with platelet counts below 50 × 109/L.
another opportunity to return!
unbelivable
how ugly I see it for shorts!
The Company expects to provide a clinical update on the Phase 1a dose escalation study in the first half of 2022.
Give us good results!
I stopped shortly after the split.
Good for BLUE but I don't think it can go back to its former glory!
I returned to TSVT just three sessions ago!
I think this good news also affects TSVT
I stopped shortly after the split.
Good for BLUE but I don't think it can go back to its former glory!
I returned to TSVT just three sessions ago!
I think this good news also affects TSVT
I would like a dozen sessions like this!
how important it is to know how to diversify!
up the ante
thank you
Wow!
7 is near
life goes on!
What other bad news could come out?
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
https://srobotics.org/2022-annual-meeting/#agendas
https://d1io3yog0oux5.cloudfront.net/_782e6a6c8a853ae04b5206703e5fb790/titanmedicalinc/db/1086/9873/pdf/Titan+-+IR+Presentation+-+post+HCW+Conf+.pdf
https://www.ldmicro.com/profile/tmdi/insiders
why hasn't the price gone down?
the savings are not that substantial!
obviously he was the highest paid!
Is it because it's less useful or has someone offered him more and Titan can't offer more?
have they finished developing?
what scares the shorts?
why don't they make me buy it at 0.25?
more than chasing marketing ... they are ready to liquidate everything
also interesting here!
Yes, yes
took a handful!
in the middle of the year it seems to me that results are expected and at these prices ...
I don't know whether to wait for them to let off steam a little longer before returning
maybe next week
I am tempted
This risk-adjusted analysis demonstrates that the safety profile of pacritinib 200 mg BID is comparable to BAT. In particular, rates of bleeding were not elevated on pacritinib 200 mg BID compared to BAT, both overall and in patients with PLT <50 x 109/L. Rates of fatal events, thrombosis, major adverse cardiac events (MACE) and non-melanoma skin cancer were higher on ruxolitinib than pacritinib. These results indicate that pacritinb 200 mg BID may represent a full-dose therapeutic option for patients with myelofibrosis, including those with thrombocytopenia.
good good good...
JDS1 LLC - CALLS
https://sec.report/Document/0001171520-22-000346/
What are you doing with 87 million?
Why don't you give them to us?